Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Nurix Therapeutics, Inc. (NRIX : NSDQ)

• Company Description    Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company's product candidates include NX-2127 and NX-1607 which are in clinical stage. Nurix Therapeutics Inc.is based in San Francisco, California. Number of Employees: 317

• Price / Volume Information    Yesterday's Closing Price: $25.34 Daily Weekly Monthly 20 Day Moving Average: 2,449,025 shares Shares Outstanding: 109.25 (millions) Market Capitalization: $2,768.40 (millions) Beta: 1.82 52 Week High: $28.23 52 Week Low: $10.38 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 7.15% 8.28% 12 Week 7.46% 4.84% Year To Date 33.58% 20.12%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1600 SIERRA POINT PKWY - BRISBANE,CA 94005 USA ph: 415-660-5320 fax: - kfortner@nurixtx.com http://www.nurixtx.com

• General Corporate Information    Officers Arthur T. Sands - President and Chief Executive Officer Julia P. Gregory - Chairman Hans van Houte - Chief Financial Officer Roy D. Baynes - Director Roger Dansey - Director Peer Information Nurix Therapeutics, Inc. (CORR.) Nurix Therapeutics, Inc. (RSPI) Nurix Therapeutics, Inc. (CGXP) Nurix Therapeutics, Inc. (BGEN) Nurix Therapeutics, Inc. (GTBP) Nurix Therapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 67080M103 SIC: 2834 Fiscal Year Fiscal Year End: November Last Reported Quarter: 08/01/26 Next Expected EPS Date: 01/27/27 Share - Related Items Shares Outstanding: 109.25 Most Recent Split Date: (:1) Beta: 1.82 Market Capitalization: $2,768.40 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.46 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $1.14 Payout Ratio: 0.00 Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 01/27/27

• Fundamental Ratios P/E Current FY Estimate: 22.20 Trailing 12 Months: 10.97 PEG Ratio: - Price Ratios Price/Book: 2.86 Price/Cash Flow: - Price / Sales: 3.94 EPS Growth vs. Year Ago Period: 559.22% vs. Previous Quarter: 683.95% Sales Growth vs. Year Ago Period: 8,426.27% vs. Previous Quarter: 7,342.93% ROE 08/31/26 - 49.34 05/31/26 - -76.09 02/28/26 - -64.21 ROA 08/31/26 - 38.61 05/31/26 - -57.31 02/28/26 - -48.44 Current Ratio 08/31/26 - 8.44 05/31/26 - 6.34 02/28/26 - 6.01 Quick Ratio 08/31/26 - 8.44 05/31/26 - 6.34 02/28/26 - 6.01 Operating Margin 08/31/26 - 42.01 05/31/26 - -928.44 02/28/26 - -411.37 Net Margin 08/31/26 - 42.01 05/31/26 - -928.44 02/28/26 - -411.37 Pre-Tax Margin 08/31/26 - 43.91 05/31/26 - -929.18 02/28/26 - -410.32 Book Value 08/31/26 - 8.86 05/31/26 - 3.89 02/28/26 - 4.65 Inventory Turnover 08/31/26 - - 05/31/26 - - 02/28/26 - - Debt-to-Equity 08/31/26 - 0.00 05/31/26 - 0.00 02/28/26 - 0.00 Debt-to-Capital 08/31/26 - 0.00 05/31/26 - 0.00 02/28/26 - 0.00

Powered by Zacks Investment Research ©